Name: Tannaz Zebardast
Qualification: Pharm.D, Ph.D in medicinal chemistry
Nationality: Iranian
Marital Status : single
Date and place of birth: 19/8/1981 Tehran ,Iran
Title: Assistant Professor
Address: Department of Pharmaceutical Chemistry , Faculty of Pharmaceutical

Chemistry, Pharmaceutical Sciences Branch, Tehran-Iran (IAUPS)

E-Mail :Tannazzebardast@yahoo.com

Dr-zebardast@iaups.ac.ir

Education:
Pharm D (Faculty of Pharmacy, Islamic Azad University, Tehran, Iran,2000-2005)

Ph.D in Medicinal Chemistry (Shahid Beheshti, , University of Medical Sciences,

Tehran ,Iran, 2006-2011)

Work experience:
Teaching assistant, Shahid Beheshti University of Medical Science,
Tehran ,Iran.(2005-2010).

Teaching assistant in"Organic chemistry" and instrumental analysis labs.

Assistant Professor in medicinal and pharmaceutical chemistry, , Faculty of

Pharmaceutical Chemistry, Islamic Azad University of Medical Sciences.Tehran-Iran

(2013 to now).

Head of department of pharmaceutical chemistry , Islamic Azad University of Medical Sciences. Tehran-Iran.(2014-2019).

Head of department of applied chemistry , Islamic Azad University of Medical Sciences. Tehran-Iran.(2014-2019).

Head of department of nanochemistry, Islamic Azad University of Medical Sciences. Tehran-Iran.(2014-2019).

Deputy od educational of pharmaceutical chemistry , Islamic Azad University of Medical Sciences. Tehran-Iran.(2015-2016).

Member of food and drug department of iran university of medical sciences. Tehran-Iran.(2018 to now).

Research interests:

Drug design , drug synthesis and biological evaluation of anti cancer effects

specially enzyme inhibitors(COX-2 inhibitors) .

Anti HIV drug design and synthesis.

Molecular modeling studies.

Publications:

1-Zarghi, A.; **Zebardast, T**.; Hakimion, F.; Shirazi, H. F.;Rao, P. N. P.; Knaus, E. E. Design,Synthesis and biological evaluation of chalcone derivatives possessing a methansulfonamido or an azido pharmacophore as selective COX-2 Inhibitors .Bioorg. Med. Chem. (USA) 2006, 14,7044.

2-**Zebardast, T**.; Zarghi, A.; Daraie, B.; Hedayati, M.; Dadrass, O. G. Design and synthesis of 3-alkyl-2-aryl-1,3-thiazinan-4-one derivatives
as selective cyclooxygenase (COX-2) inhibitors. Bioorg. Med.Chem. Lett.(USA). 2009, 19, 3162**.**

3- Zarghi, A.; **Zebardast, T**.; Daraei, B.; Hedayati, M**.** Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg. Med. Chem.(USA) .2009, 17,5369.

4- Zarghi, A**.; Zebardast, T** ; Hajighasemali,F; Alipoor,E ;Daraie[c],B;Hedayati M. Design and synthesis of new 1, 3-benzdiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Arch. Pharm.(Germany).2011.

5- Zebardast ,T, Zarghi,A **,**Salehiniya,H. Design and Synthesis of New Biarylhydrazides Possessing an Azido Pharmacophore as Selective COX-2 Inhibitors.Journal of pharmaceutical of science(IRAN).2013,1(4),267.

6-Akbari,S.;Zebardast,T.;Zarghi,A.;Hajimahdi,Z.QSAR modeling of COX-2 inhibitory activity of some dihydropyridine and hydroquinoline derivatives using multiple linear regression (MLR) method. Iranian Journal of Pharmaceutical Research.2017,16(2),525-532.

7- Faraji,N.; Zebardast,T.;, Zarghi,A.; Hajimahdi,**Z.** QSAR Modeling of Aminopeptidase N/CD13 (APN) Inhibitory Activity ofsome Leucine Ureido Derivatives by GA-MLR and SW-MLR Methods. Letters in Drug Design & Discovery. 2017, 14, 1348-1357.

8- Akbarpour Avinia , S.; Zebardast ,T.; Hajimahdi, Z and Zarghi ,A. QSAR Modeling of COX-2 Inhibitory Activity of Thiazinan, Benzthiazinan, and Benzdiazinan Derivatives.Int Pharmacy Acta.2018,1,190-197.

9-Hajimahdi,Z ;Faghihi,K; Safakish,M; Zebardast,T ;Zarghi,A. Molecular Docking and QSAR Study of 2-Benzoxazolinone, Quinazoline and Diazocoumarin Derivatives as Anti-HIV-1 Agents. Iranian Journal of Pharmaceutical Research.(in press)2019

10- A.Zarghi,T.Zebardast,F.shirazi. Design, synthesis and invitro antitumor evaluation of new 2,3 diarylindenopyrazole , 2,3diarylbenzindazole,2,3diarylchromenopyrazole and 2,3diarylbenzofuropyrazole derivatives as selective COX-2 inhibitors.(Manuscript preparation).

11- Design and synthesis of benzoxazinone derivatives possessing a methylsulfonyl pharmacophore as selective COX-2 inhibitors.(Manuscript preparation).

Presentation:

1- T. Zebardast, A. Zarghi. Design,Synthesis and biological evaluation of chalcone derivatives possessing an azido pharmacophore as selective COX-2 Inhibitors. In MPC. 2006. Turkey.

2-T. Zebardast, A. Zarghi. Design,Synthesis and biological evaluation of chalcone derivatives possessing a methansulfonamido pharmacophore as selective COX-2 Inhibitors. In BPC. 2007. UK.

3- T. Zebardast, A. Zarghi. Design and synthesis of biphenyl hydrazid derivatives possessing an azido pharmacophore as selective COX-2 Inhibitors. In IPSC. 2008. IRAN.

4- T. Zebardast, A. Zarghi. Design and synthesis of benzoxazinone derivatives possessing a methylsulfonyl pharmaciphore as selective COX-2 inhibitors. in IPSC 2010.IRAN.

5- T. Zebardast, A. Zarghi, ، F, Shirazi. Design ,synthesis and invitro anti tumor evaluation of new 2, 3-diaryl-indenopyrazole and 2,3-diaryl-benzofuropyrazole derivatives as selective cyclooxygenase (COX-2) inhibitors.In IPSC.2012.

6-S.akbari,T.Zebardast,Z.Hajimahdidevelopment of QSAR model of selective COX-2 inhibitors using multiple lenear regression method (MLR).In IPSC.2015.

7-T.Zebardast,A.zarghi. Design and Synthesis and invitro antitumor evaluation of new 2,3 biphenyl benzindazole and 2-phenyl-3-ptolylchromeno pyrazole derivatives as selective cox-2 inhibitors. In IPSC.2015.

8--N.Faraji,Z.Hajimahdi,T.Zebardast.Computational studies the molecular connections of aminopeptidase inhibitors as anti canser agents. 14st Congress of Biochemistry. Iran.2016.

9- N.Faraji,Z.Hajimahdi,T.Zebardast .Quantitayive structure activity relationship (QSAR) study on new inhibitors of angiogenesis with anti cancer activity.1st iranian medicinal chemistry seminar.(IMCS).2016.

10- N.Faraji,Z.Hajimahdi,T.Zebardast. Docking studies of histone deacetylase inhibitors as anti cancer agents. 14st Congress of Biochemistry. Iran.2016.

11-M.roohi,H.mohammadsalehi,T.Zebardast,Z.Hajimahdi.Docking studies and synthesis of N-(4-oxo-2phenyl-1,4-dihydroquinazolin-3(2H)-ylbenzamide derivatives as inhibitors of HIV replication.In IPSC 2015.

12- F. Karimi, T.Zebardast,Z.Hajimahdi, A. zarghi. Design, synthesis and molecular modeling studies of novel 3-benzimidazolyl-2,3-dihydroquinazoline-4-one derivatives as anti-HIV-1 agents.Pharmacy Updates 2019.

13- N. Faraji Jalali , T.Zebardast ,Z.Hajimahdi, A. zarghi. Design, Synthesis and docking study of novel 1,3-benzdiazinane-4-one derivatives as anti-HIV-1 agents. Pharmacy Updates 2019.

14-M.Goodarzi, T.Zebardast,S.Amidi,M.Esfahanizadeh,F.Kobarfard.Design and synthesis of a group of chalcone derivatives as antiplatelet agents. Pharmacy Updates 2019.

Books:

F H shirazi,A zarghi, A ashtarinezhad, F kobarfard, M nakhjavani, N anjidani, R zendehdel, S arfaie, Sh shobeiri, Sh mohebi,T zebardast,Remarks in successful cellular investigations for fighting breast cancer using novel synthetic compound Intech open access publisher ,2011

Supervisor:

Pharm D and MS thesis (more than 20 items)

Awards:

2 st place in PhD board exam in medicinal chemistry

Best poster presentation in Mediterranean PharmacyCongress,Mersin,Turkey,2006.

Best poster presentation in 12th Iranian Pharmaceutical Sciences Congress ,

Zanjan ,Iran ,2010.

Contact:

Mobile cell:00989122148550

Tel:00982122640051-5

Address: Department of Pharmaceutical Chemistry , Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University.Tehran-Iran (IAUPS)

E-Mail :Tannazzebardast@yahoo.com

Dr-zebardast@iaups.ac.ir